Source-grounded facts extracted from Werewolf Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Werewolf Therapeutics, Inc. reported first quarter ended March 31, 2026 results: net income Net loss was $13.5 million for the first quarter of 2026.
“Net loss was $13.5 million for the first quarter of 2026, compared to $18.1 million for the same period in 2025.”
Werewolf Therapeutics, Inc. reported full year ended December 31, 2025 results: net income Net loss was $60.8 million.
“Net loss was $60.8 million for the full year 2025”
Werewolf Therapeutics, Inc. reported quarter ended December 31, 2025 results: net income Net loss was $8.4 million.
“Net loss was $8.4 million for the fourth quarter of 2025”
Werewolf Therapeutics, Inc. announced a restructuring with charges of approximately $4.1 million (64% of the Company’s workforce).
“estimates that it will record a one-time charge in the first quarter of 2026 related to employee separation benefits, including severance and related benefits, of approximately $4.1 million, all of which is anticipated to result in cash expenditures to be incurred in the first quarter of 2026. The Company may also incur additional costs not currently contemplated”
Werewolf Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A), 5810(c)(3)(H)).
“February 4, 2026, Werewolf Therapeutics, Inc. (the “Company”) received a deficiency letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the bid price for the Company’s common stock had closed below $1.00 per share, which is the minimum bid price required to maintain continued listing on the Nasdaq Global Select Market under Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Requirement”). The Notice has no immediate effect on the listing of the Company’s co”
Werewolf Therapeutics, Inc. received a nasdaq noncompliance notice notice (rules 5605(c)(2), 5605(c)(4)(B)).
“October 2, 2025, the Company notified Nasdaq of the resulting non-compliance with Nasdaq listing rules caused by Dr. Lazarus’s passing. Pursuant to Nasdaq Listing Rule 5605(c)(4)(B), the Company is entitled to a cure period to regain compliance with Nasdaq Listing Rule 5605(c)(2), which cure period will expire upon the earlier of the Company’s next annual meeting of stockholders or September 30, 2026. The Company also informed Nasdaq that the Board plans to regain compliance with the listing rules at its earliest opportunity by appointing an additional independent director of the Company to fi”
Werewolf Therapeutics, Inc.: Adopted Third Amended and Restated Bylaws to revise stockholder nomination procedures, clarify meeting presiding officers, and make administrative changes (effective 2025-06-12).
“On June 12, 2025, the board of directors of Werewolf Therapeutics, Inc. (the “Company”) adopted amended and restated bylaws of the Company (as amended and restated, the “Third Amended and Restated Bylaws” ), effective immediately, in order to, among other things: (a) revise and clarify certain procedural mechanics and informational requirements in connection with stockholder nominations of directors and submissions of stockholder proposals pursuant to the advance notice provisions of the Third Amended and Restated Bylaws, including by defining certain terms and requiring such stockholder to update such notice, if necessary, so that it remains true and correct closer to the meeting date; (b) specify individuals who may preside over meetings of the Company’s stockholders; and (c) make other administrative, modernizing, clarifying and conforming changes.”
Werewolf Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).
“May 13, 2025, Werewolf Therapeutics, Inc. (the “Company”) received a deficiency letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the bid price for the Company’s common stock had closed below $1.00 per share, which is the minimum bid price required to maintain continued listing on the Nasdaq Global Select Market under Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Requirement”). The Notice has no immediate effect on the listing of the Company’s common”
Anil Singhal, Ph.D. was appointed as Director at Werewolf Therapeutics, Inc..
“On February 19, 2025, the Board of the Company, upon recommendation of the Board’s Nominating and Corporate Governance Committee, appointed Anil Singhal, Ph.D., as a director.”
Derek DiRocco, M.D. resigned as Director at Werewolf Therapeutics, Inc..
“On February 19, 2025, Derek DiRocco, M.D., notified Werewolf Therapeutics, Inc. (the “Company”) of his intent to resign from the Board of Directors (the “Board”) of the Company, effective upon the Company’s 2025 annual meeting of stockholders.”
Werewolf Therapeutics, Inc. reported first quarter ended March 31, 2024 results: revenue $0.7 million.
“be sufficient to fund operational expenses and capital expenditure requirements through at least the first quarter of 2026. • Collaboration revenue: Collaboration revenue was $0.7 million for the first quarter of 2024, compared to $4.5 million for the same period in 2023. Collaboration revenue consists of revenue recognized from the Company’s licensing agreement”
Werewolf Therapeutics, Inc. reported quarter ended December 31, 2023 results: revenue $1.5 million.
“Collaboration revenue was $1.5 million for the fourth quarter of 2023, compared to $7.3 million for the same period in 2022”
Cynthia Seidel-Dugan departed as Chief Scientific Officer at Werewolf Therapeutics, Inc..
“On March 3, 2024, Cynthia Seidel-Dugan, Ph.D., notified the Company of her intent to retire from her position as Chief Scientific Officer of the Company, effective as of March 29, 2024.”
Michael B. Atkins was appointed as director at Werewolf Therapeutics, Inc..
“On January 4, 2024, the Board of Directors (the “Board”) of Werewolf Therapeutics, Inc. (the “Company”), upon recommendation of the Board’s Nominating and Corporate Governance Committee, appointed Michael B. Atkins, M.D., as a director.”
Werewolf Therapeutics, Inc. reported the third quarter ended September 30, 2023 results: revenue $5.9 million.
“Collaboration revenue was $5.9 million for the third quarter of 2023, compared to $5.0 million for the same period in 2022.”
Werewolf Therapeutics, Inc. reported the second quarter ended June 30, 2023 results: revenue $8.1 million, net income $5.1 million.
“Collaboration revenue was $8.1 million for the second quarter of 2023, compared to $4.1 million for the same period in 2022.”
Werewolf Therapeutics, Inc.: Adopted amended and restated bylaws to amend stockholder meeting procedures, eliminate outdated requirements, update advance notice provisions, and make other changes (effective 2023-06-21).
“On June 21, 2023, the board of directors (the “Board”) of Werewolf Therapeutics, Inc. (the “Company”) adopted amended and restated bylaws of the Company (as amended and restated, the “Second Amended and Restated Bylaws”), effective immediately to, among other things: • Amend certain procedures governing notice of each meeting of stockholders, including providing the record date for determining stockholders entitled to vote at the meeting; • Eliminate the former requirement regarding availability of the voting list during stockholder meetings, consistent with recent amendments to Section 219 of the Delaware General Corporation Law (the “DGCL”); • Clarify the procedures governing adjournment of the stockholder meetings, consistent with recent amendments to Section 222 of the DGCL; • Revise and enhance the procedures and disclosure requirements set forth in the advanced notice bylaw provision in connection with stockholder nominations of directors and submission of stockholder proposals,”
Werewolf Therapeutics, Inc. shareholders approved Ratification of Appointment of Ernst & Young LLP as Independent Registered Public Accounting Firm at the 2023-06-21 meeting.
“The stockholders of the Company ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The results of the stockholders’ vote with respect to such ratification were as follows: For Against Abstain 29,895,437 3,279 1,400”
Werewolf Therapeutics, Inc. shareholders approved Election of Class II Directors at the 2023-06-21 meeting.
“The stockholders of the Company elected Meeta Chatterjee, Ph.D., Derek DiRocco, Ph.D., and Daniel J. Hicklin, Ph.D. as Class II directors, each for a three-year term ending at the annual meeting of stockholders to be held in 2026. The results of the stockholders’ vote with respect to the election of the Class II directors were as follows: Name Votes For Votes Withheld Broker Non-Votes Meeta Chatterjee, Ph.D. 18,766,485 4,810,351 6,323,280 Derek DiRocco, Ph.D. 18,471,357 5,105,479 6,323,280 Daniel J. Hicklin, Ph.D. 23,547,794 29,042 6,323,280”
Werewolf Therapeutics, Inc. reported the first quarter ended March 31, 2023 results: revenue Collaboration revenue was $4.5 million.
“sufficient to fund its operational expenses and capital expenditure requirements through at least the fourth quarter of 2024. • Collaboration revenue: Collaboration revenue was $4.5 million for the first quarter of 2023, compared to zero for the same period in 2022. Collaboration revenue is related to partial recognition of the $15.0 million upfront payment received”
Werewolf Therapeutics, Inc. updated its the fourth quarter and full year ended December 31, 2022 guidance (raised).
“On March 23, 2023, Werewolf Therapeutics, Inc., a Delaware corporation (the “Company”), issued a press release announcing financial results for the quarter ended December 31, 2022.”
Werewolf Therapeutics, Inc. amended First Amendment to Amended and Restated Loan and Security Agreement with Pacific Western Bank (effective 2023-03-16).
“On March 16, 2023, Werewolf Therapeutics, Inc. (the “Company”) entered into a First Amendment to Amended and Restated Loan and Security Agreement (the “First Amendment”) with Pacific Western Bank (“PWB”), which amended that certain Amended and Restated Loan and Security Agreement dated as of April 12, 2022, by and between the Company and PWB.”
Werewolf Therapeutics, Inc. reported third quarter ended September 30, 2022 results: revenue $5.0 million.
“sufficient to fund its operational expenses and capital expenditure requirements through at least the second quarter of 2024. • Collaboration revenue: Collaboration revenue was $5.0 million for the third quarter of 2022, compared to zero for the same period in 2021. Collaboration revenue is related to amortization of the $15.0 million upfront payment received in”
Sakae Asanuma resigned as Director at Werewolf Therapeutics, Inc..
“On April 12, 2022, Sakae Asanuma submitted his resignation from the Board of Directors of the Company effective as of April 15, 2022.”
Meeta Chatterjee, Ph.D. was appointed as Director at Werewolf Therapeutics, Inc..
“On October 28, 2021, the Board of Directors (the “Board”) of Werewolf Therapeutics, Inc. (the “Company”), upon recommendation of the Board’s Nominating and Corporate Governance Committee, appointed Meeta Chatterjee, Ph.D., as a director.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.